GlassScriptPhysician profile
Eva K Miller
NPI 1225161482
$141,347.63
in general payments reported to CMS, 2019-2025
24 companies · $18K in 2025
The $18K reported for 2025 was more than what 91% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $12K · 2021: $24K · 2022: $27K · 2023: $9,865 · 2024: $18K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $5,042 · Travel and Lodging: $1,566 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,090.00 |
| Food and Beverage | $5,041.93 |
| Travel and Lodging | $1,566.18 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $131,924.84 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $4,124.31 | 2022-2025 | Tezspire |
| Genzyme Corporation | $1,103.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $740.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $590.20 | 2019-2025 | Dupixent |
| Pfizer INC. | $490.08 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $297.42 | 2025 | Neffy |
| Csl Behring | $274.48 | 2022-2025 | Hizentra, Privigen |
| Novartis Pharmaceuticals Corporation | $267.31 | 2019-2025 | |
| Kaleo, INC. | $263.18 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $251.85 | 2019-2025 | Xolair |
| Optinose US, INC. | $235.50 | 2020-2025 | |
| Alk-Abello, INC | $138.86 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.64 | 2021-2025 | Cuvitru, Eohilia |
| Grifols USA, LLC | $122.36 | 2024-2025 | Xembify |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $96.27 | 2019-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.54 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $51.63 | 2025 | Alvesco |
| Greer Laboratories, INC. | $49.78 | 2019-2024 | Palforzia |
| Aimmune Therapeutics, INC. | $39.41 | 2021 | |
| Organon LLC | $28.46 | 2025 | Vtama |
| Cycle Pharmaceuticals INC | $25.47 | 2025 | Sajazir |
| Octapharma USA, INC. | $19.54 | 2024 | Cutaquig |
| Galderma Laboratories, L.P. | $16.06 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.